Targeted-release budesonide should be an option for treating patients in England with primary immunoglobulin A nephropathy, the National Institute for Health and Care Excellence (NICE) said.

Calliditas Therapeutics AB’s full approval from the U.S. FDA for Tarpeyo (budesonide) delayed release capsules in immunoglobulin A nephropathy (IgAN) revived speculation about competitor Travere ...

Managing complex medication schedules could soon become as simple as taking a single capsule each day. Engineers at the University of California San Diego have developed a capsule that can be packed ...

AstraZeneca, a global, innovation-driven biopharmaceutical business, has entered into an agreement with Perrigo Company plc, a top five global OTC consumer goods and pharmaceutical company, for the ...